CAS 51953-17-4 - Manufacturers, Factory, Suppliers from China

CAS 51953-17-4, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

4-Hydroxypyrimidine CAS 51953-17-4 Purity ≥98.5% (HPLC) Factory High Quality
Read More

Fmoc-Asp-OtBu CAS 129460-09-9 Assay ≥98.5% (HPLC)

Fmoc-Cys(Dpm)-OH CAS 247595-29-5 Assay ≥98.0% (HPLC)

Fmoc-D-Asn(Trt)-OH CAS 180570-71-2 Assay ≥99.0% (HPLC)

Fmoc-Cys(Mtt)-OH CAS 269067-38-1 Assay ≥98.0% (HPLC)

Fmoc-Dap-OH CAS 181954-34-7 Assay ≥98.0% (HPLC)

Fmoc-D-Arg(Pbf)-OH CAS 187618-60-6 Purity ≥98.5% (HPLC) Factory

Top Selling Products

Related Blog
Reviews

New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...
Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
Yellow phosphorus and phosphoric acid rose together

Yellow phosphorus and phosphoric acid rose together Yunnan-guizhou yellow phosphorus prices rose.Data show that the offer of 34500 yuan/ton at the beginning of the week has risen to 60,000 yuan/to...
Method Of Analyzing Palladium Content In Palladium Catalysts

1. Abstract Enrichment palladium of palladium catalysts by pyrometallurgy, then dissolve the palladium in admixture acid, the liquid is analyzed by AAS. 2. Reagent 2.1 Hydrochloric acid(ρ1.19g/ml) ...
The 3rd China International Biological & Chemical Pharmaceutical Industry Conference

The 3rd CMC-China 2021 Time: September 29-30, 2021 Exhibition Venue: C-D Hall, Suzhou International Expo Center, Suzhou City, JIangsu Province, China. Synergy of Centralized China’s Drug Volume-ba...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...

2022.07.27 18:27:44
2022.06.30 03:14:51
2022.03.20 16:47:26
2022.03.18 22:32:15
2022.01.09 05:55:41
2021.11.03 20:36:16

CAS 51953-17-4 - Manufacturers, Factory, Suppliers from China

Related Products

4-Hydroxypyrimidine CAS 51953-17-4 Purity ≥98.5% (HPLC) Factory High Quality

Fmoc-Asp-OtBu CAS 129460-09-9 Assay ≥98.5% (HPLC)

Fmoc-Cys(Dpm)-OH CAS 247595-29-5 Assay ≥98.0% (HPLC)

Fmoc-D-Asn(Trt)-OH CAS 180570-71-2 Assay ≥99.0% (HPLC)

Fmoc-Cys(Mtt)-OH CAS 269067-38-1 Assay ≥98.0% (HPLC)

Fmoc-Dap-OH CAS 181954-34-7 Assay ≥98.0% (HPLC)

Fmoc-D-Arg(Pbf)-OH CAS 187618-60-6 Purity ≥98.5% (HPLC) Factory

Top Selling Products

Fmoc-Cys(Trt)-OH CAS 103213-32-7 Fmoc-S-Trityl-L-Cysteine Purity >99.0% (HPLC)

2'-Iodoacetophenone CAS 2142-70-3 Purity >98.0% (GC)

Maltol CAS 118-71-8 (3-Hydroxy-2-Methyl-4-Pyrone) Purity ≥99.0% (HPLC)

1,1-Cyclohexanediacetic Anhydride (CAA) CAS 1010-26-0 Purity >99.0% (HPLC) Gabapentin Intermediate

D-tert-Leucine (H-D-Tle-OH) CAS 26782-71-8 Assay ≥98.5% (Titration)

Boc-Asp(OtBu)-OH CAS 1676-90-0 Purity >98.0% (HPLC) Factory

Rivaroxaban CAS 366789-02-8 Purity >99.5% (HPLC) Factory API High Quality

α,α'-Dibromo-p-Xylene CAS 623-24-5 Purity >98.0% (GC)

H-Met-OMe·HCl CAS 2491-18-1 L-Methionine Methyl Ester Hydrochloride Purity >98.0% (HPLC)

S-Ethylisothiourea Hydrobromide CAS 1071-37-0 Purity >98.0% Ensitrelvir (S-217622) Intermediate COVID-19

3-Methyl-2-Butanone CAS 563-80-4 Purity >99.5% (GC)

3-(1-Naphthyl)-L-Alanine CAS 55516-54-6 (H-1-Nal-OH) Purity >98.5% (HPLC)

New COVID treatments offer hope

Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Yellow phosphorus and phosphoric acid rose together

Method Of Analyzing Palladium Content In Palladium Catalysts

The 3rd China International Biological & Chemical Pharmaceutical Industry Conference

Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

2022.07.27 18:27:44

2022.06.30 03:14:51

2022.03.20 16:47:26

2022.03.18 22:32:15

2022.01.09 05:55:41

2021.11.03 20:36:16

related search